Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00078468 · ClinicalTrials.gov registry record · Phase 2
Study of the GARFT Inhibitor AG2037 in Patients With Metastatic Colorectal Cancer Who Failed Treatment
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 56
- Enrollment target
NCT00078468 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 56 participants.
The verdict
NCT00078468, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 56 participants
- Enrollment target
Study Summary
To determine the response rate in patients with metastatic colorectal cancer who failed treatment with a 5-Fluorouracil/Leucovorin regimen and up to one other chemotherapeutic regimen (not including adjuvant chemotherapy).
Interventions
- DRUG PELITREXOL/AG-2037
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2003-12 |
| Est. Completion | 2004-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00078468
The ClinicalTrials.gov registry entry for NCT00078468 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PELITREXOL/AG-2037 is the first listed.
NCT00078468 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00078468 about?
NCT00078468 is a clinical study titled "Study of the GARFT Inhibitor AG2037 in Patients With Metastatic Colorectal Cancer Who Failed Treatment". To determine the response rate in patients with metastatic colorectal cancer who failed treatment with a 5-Fluorouracil/Leucovorin regimen and up to one other chemotherapeutic regimen (not including adjuvant chemotherapy).
What is the current status of trial NCT00078468?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 56 participants. The study started on 2003-12. Estimated completion is 2004-09.
What interventions are being tested in trial NCT00078468?
The interventions under investigation include: PELITREXOL/AG-2037 (DRUG).
Who is sponsoring clinical trial NCT00078468?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.